Eli Lilly's CEO Discusses Obesity, Diabetes, and GLP-1 Drugs

Eli Lilly's innovative GLP-1 drugs are transforming obesity treatment, offering hope for millions while facing scrutiny over pricing and access.

### The Obesity Epidemic and Eli Lilly's Role in Addressing It
* 🎙 In a recent interview, Dave Ricks, CEO of Eli Lilly, discussed the company's significant impact on the pharmaceutical industry, particularly in the **GLP-1 drug market**, which analysts predict could reach **$150 billion in annual revenue** within a decade.
* 📈 Since Ricks took over in January 2017, Eli Lilly's market cap **skyrocketed from $70 billion to an impressive $878 billion**, with projected revenues of **$46 billion this year**, showcasing an **extraordinary growth trajectory**.
* 🍔 The conversation highlighted the **alarming obesity epidemic**, with **74% of Americans classified as overweight or clinically obese**, a condition that has escalated into a **global health crisis affecting billions**.
* 📊 Ricks pointed out that the average daily caloric intake in the U.S. has **surged from 2,800 to 3,600 calories** since 1961, contributing to rising obesity rates, which now see **51% of Americans classified as either obese or severely obese**.
* 💔 Obesity is linked to over **230 chronic health conditions**, including type 2 diabetes, cardiovascular disease, and fatty liver disease, with diabetes alone affecting **millions** and significantly increasing the risk of **severe health complications**.
* 💡 Eli Lilly has pioneered treatments for diabetes, being the **first American company to produce insulin**, and has since developed GLP-1 drugs that not only **manage diabetes** but also **promote weight loss**, addressing the **root causes of obesity**.
* The company is investing heavily in research, with **105 clinical studies underway** for various indications of obesity-related diseases, aiming to demonstrate that **weight loss can lead to substantial health benefits** and potentially **prevent diabetes**.
* 💰 Ricks acknowledged the challenges of insurance coverage for obesity treatments, emphasizing the **need for a shift in how healthcare systems view and reimburse preventative measures** rather than just reactive treatments for existing conditions.

### Innovations in Weight Management and Pharmaceutical Advancements
* 💊 Long-term use of weight management drugs may help **reset the body's metabolic thermostat**, potentially allowing for **sustained weight loss after discontinuation**, though this is still under research.
* 📉 Individuals often experience a **decline in metabolism** after stopping these medications, leading to **weight gain** even when consuming a normal caloric intake of **1500 to 2500 calories**.
* 🔬 New drug developments, such as an oral GLP-1 treatment called ororon, aim to provide **easier administration and scalability**, which could **alleviate current supply shortages**.
* 🍏 Studies indicate that users of GLP-1 drugs are purchasing **fewer calories and more nutritious foods**, suggesting a **potential shift in consumer behavior** within the food industry.
* 📊 Eli Lilly has seen significant financial success, reporting **$11 billion in revenue** in the last quarter, with projections indicating a potential increase to **$32 billion in operating income** by 2026.
* 🏥 The company emphasizes a **long-term investment strategy** in research and development, allocating **over $11 billion annually** to innovate and sustain its drug pipeline.
* 🧬 Lilly is exploring various therapeutic avenues beyond weight management, including **cancer, immunology, and neuroscience**, to ensure a diverse portfolio that addresses **unmet medical needs**.
* 🤖 The integration of AI in drug discovery is being approached cautiously, with a focus on **enhancing existing processes** rather than relying solely on in silico methods for **new drug development**.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

Chamath Palihapitiya, Jason Calacanis, David Sacks & David Friedberg cover all things economic, tech, political, social & poker.

Follow the besties: 
https://twitter.com/chamath
https://twitter.com/Jason
https://twitter.com/DavidSacks
https://twitter.com/friedberg

Follow the pod: 
https://twitter.com/theallinpod
https://www.instagram.com/theallinpod
https://www.tiktok.com/@all_in_tok
https://www.linkedin.com/company/allinpod

Subscribe to our clips channel for the best of the besties:
https://www.youtube.com/@allinpod?sub_confirmation=1


All-In Podcast

The Impact of Obesity and Eli Lilly's Role

Eli Lilly, led by CEO Dave Ricks, has experienced remarkable growth, with a market cap rising from $70 billion in 2017 to $878 billion today, driven by the GLP-1 drug market.

The obesity epidemic is a global crisis, with 74% of Americans now overweight or obese, and the problem is projected to affect a billion people worldwide by 2030.

The increase in calorie consumption and the rise of ultra-processed foods are key factors contributing to the epidemic, which is linked to various chronic health conditions.

The Impact of Fatty Liver Disease and Obesity

Fatty liver disease has become common in obese individuals, leading to liver fibrosis and severe health issues.

The obesity epidemic is linked to 230 diseases, including type 2 diabetes, obstructive sleep apnea, and mood disorders.

The history of insulin production and the discovery of GLP-1 have played crucial roles in addressing the rising rates of diabetes and its complications.

The History and Impact of GLP-1 in Diabetes Treatment

GLP-1, a hormone that stimulates insulin production, was discovered in 1987 and became the first peptide drug for diabetes.

The native form of GLP-1 has a short half-life, leading to the development of longer-lasting analogs, with Lily and Nova Nordisk playing key roles.

The evolution of GLP-1 drugs from daily to weekly injections allowed for higher dosing and improved patient outcomes, while also revealing their impact on weight loss and other organs in the body.

The Role of GLP-1 in Metabolism and Weight Loss

GLP-1 is a hormone that signals the body to feel fed, impacting heart rate, lipid levels, and nutrient absorption.

It has primary and secondary effects on metabolism, with potential uses for obesity and other health issues.

The innovation in GLP-1-based drugs is aimed at providing more potent weight loss solutions and addressing various chronic diseases associated with obesity.

The Controversy of Weight Loss Medications

Weight loss medications often require a diabetes diagnosis for access, leading to criticism and stigma associated with obesity.

The financial incentive for insurers to cover these medications is growing, but coverage is still inconsistent, with many people paying out of pocket.

The launch of direct-to-consumer models aims to address stigma and cost, while the long-term need for these drugs and their potential to create dependency remains a concern.

The Impact of GLP-1 Drugs on Weight Management and the Food Industry

GLP-1 drugs can lead to a decline in metabolism, causing weight gain when users stop taking them, but some are experimenting with flexible dosing.

An upcoming oral version of the drug, ororon, aims to simplify administration and scale production.

The use of these drugs is already influencing food purchasing habits and is expected to have a broader impact on the food industry and related health issues.

Investing in R&D and Healthcare Innovation

The company has been investing heavily in R&D since 2005, with a projected spend of over $11 billion this year.

They aim to create a sustainable healthcare model by working with various stakeholders to provide affordable access to their medicines.

The company's success in insulin pricing has been a focus, with efforts to reduce costs and invest in the next generation of therapies while also building manufacturing infrastructure in the United States.

Strategic Growth and Innovation in Pharma

The pharmaceutical industry faces unique challenges with drug patent expirations, necessitating a diverse portfolio and innovative solutions.

The company is investing in cancer, immunology, and brain disease to address unmet medical needs and drive growth.

Exciting advancements in genetic medicine, gene therapy, and protein knockdown techniques are being explored to create scalable and impactful treatments for millions of people.

Growing a Company: Leadership, Culture, and M&A Strategy

The speaker emphasizes the importance of learning from science and taking early action during company growth, using a dual approach of venture funding and direct investment.

They are expanding their project, Catalyze 360, to offer space and services to incubate small companies, while also making small bets through M&A, aiming to add value over time.

The speaker focuses on maintaining a strong company culture and alignment among employees, using a ratchet mindset to continuously improve timelines and incentivize performance.

The Impact of AI on Drug Development at Lily

Lily has significantly reduced the time to send projects to the FDA, now doing it within two weeks.

The company is expanding its science operations on the coast to attract talent and is actively partnering with tech giants for AI efforts.

While AI startups are emerging in drug discovery, Lily believes in a tool builder approach and the importance of integrating wet lab and clinic processes.